WuXi Discovery Services
Delivering our partners preclinical discoveries through world class capabilities, directed by teams with a reputation for collaboration and scientific excellence.
Solving the Complexities of T Cell Engager Development
Navigating the ADC Development Pathway
End-to-End CRDMO Platform for Oligonucleotide Drugs
Propelling Boundaries: Innovative Technologies in Early Drug Discovery
Strategies for Advancing Molecular Glue Drug Discovery
Introduction to WuXi AppTec
RCS: WuXi AppTec’s Research Chemistry Services
Integrated Screening & Assay Capabilities Facilitate Peptide Drug Discovery
What are the Key Steps in Validating Targeted Protein Degraders?
ADC Development: Preclinical Pharmacology Essentials
Targeted Protein Degraders: Trends, Challenges, and Solutions
Targeted Covalent Inhibitor Synthesis
Biotech Showcase 2025: Interview with Dr. Steve Yang, co-CEO of WuXi AppTec
Condition Optimization for Buchwald-Hartwig Reactions
Season's Greetings from WuXi AppTec
Integrated Strategies to Accelerate Preclinical Development of Antibody-Drug Conjugates
Optimized Reaction Conditions for Ni-Catalyzed Reductive Cross-coupling
Animal Disease Models of Rheumatoid Arthritis
Integrated Solutions & Research Strategies for the Discovery of Targeted Protein Degraders
Paclitaxel-Induced Resistant Tumor Models
Radionuclide Drug Conjugates
Combat Drug Resistance in Cancer Therapy
Discovery, Characterization, and Manufacture of Peptide Radiopharmaceuticals
Why isn't My PROTAC Effective?
Rare Disease Therapeutics: Accelerating Development and Improving Access